Of 67 patients with HER2-positive breast cancer treated at the RP2D of 2.3 mg/kg, two (3.0%) patients had complete response (CR; one to be confirmed) and 34 (50.7%) patients had partial response (PR; seven to be confirmed). The gene discussed is ERBB2; the disease is breast cancer.